MCID: HRD004
MIFTS: 57

Hereditary Breast Ovarian Cancer malady

Categories: Genetic diseases, Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Hereditary Breast Ovarian Cancer

Aliases & Descriptions for Hereditary Breast Ovarian Cancer:

Name: Hereditary Breast Ovarian Cancer 12 14
Hereditary Breast and Ovarian Cancer Syndrome 56 29 42 69
Breast/ovarian Cancer, Hereditary 24

Characteristics:

Orphanet epidemiological data:

56
hereditary breast and ovarian cancer syndrome
Inheritance: Autosomal dominant; Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:5683
MeSH 42 D061325
NCIt 47 C8493
Orphanet 56 ORPHA145
ICD10 via Orphanet 34 C50 C56
UMLS via Orphanet 70 C0677776
UMLS 69 C0677776

Summaries for Hereditary Breast Ovarian Cancer

Disease Ontology : 12 An autosomal dominant disease characterized by the higher than normal tendency to develop breast and ovarian cancers in genetically related families.

MalaCards based summary : Hereditary Breast Ovarian Cancer, also known as hereditary breast and ovarian cancer syndrome, is related to brca1 hereditary breast and ovarian cancer syndrome and brca2 hereditary breast and ovarian cancer syndrome. An important gene associated with Hereditary Breast Ovarian Cancer is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Letrozole and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and ovary, and related phenotypes are Decreased homologous recombination repair frequency and cellular

Wikipedia : 71 Hereditary breast–ovarian cancer syndromes (HBOC) are cancer syndromes that produce higher than normal... more...

Related Diseases for Hereditary Breast Ovarian Cancer

Diseases in the Hereditary Breast Ovarian Cancer family:

Breast-Ovarian Cancer, Familial, 2 Breast-Ovarian Cancer, Familial 4
Breast-Ovarian Cancer, Familial, 1 Breast-Ovarian Cancer, Familial 3
Rad51c-Related Familial Susceptibility to Breast-Ovarian Cancer Rad51d-Related Familial Susceptibility to Breast-Ovarian Cancer

Diseases related to Hereditary Breast Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Related Disease Score Top Affiliating Genes
1 brca1 hereditary breast and ovarian cancer syndrome 12.3
2 brca2 hereditary breast and ovarian cancer syndrome 12.3
3 pancreatic cancer 11.4
4 ovarian cancer 10.7
5 aorto-ventricular tunnel 10.3 BRCA1 BRCA2
6 lymphoproliferative syndrome, ebv-associated, autosomal, 1 10.3 CHEK2 TP53
7 lung clear cell-sugar-tumor 10.3 BRCA1 BRCA2 TP53
8 lethal congenital contracture syndrome 7 10.3 BRCA1 BRCA2 NBN
9 breast pericanalicular fibroadenoma 10.3 BRCA1 BRCA2 TP53
10 paraphimosis 10.3 BRCA1 BRCA2 TP53
11 bladder colloid adenocarcinoma 10.3 BRCA1 BRCA2 TP53
12 mediastinum synovial sarcoma 10.3 BRCA1 BRCA2 TP53
13 burn scar 10.3 BRCA1 BRCA2
14 cellular ependymoma 10.3 BRCA1 BRCA2 TP53
15 immunodeficiency due to a late component of complement deficiency 10.3 BRCA1 BRCA2 TP53
16 mycobacterium kansasii 10.3 BRCA1 BRCA2 TP53
17 kunjin encephalitis 10.2 BRCA1 BRCA2
18 estrogen-receptor positive breast cancer 10.2 BRCA1 BRCA2 TP53
19 congenital bile acid synthesis defect 10.2 BRCA2 PALB2 TP53
20 pyomyositis 10.2 BRCA1 BRCA2 TP53
21 metagonimiasis 10.2 BRCA1 BRCA2 TP53
22 autoimmune disease of cardiovascular system 10.2 BRCA1 BRCA2
23 fallopian tube carcinosarcoma 10.2 BRCA1 BRCA2 RAD51D TP53
24 dental caries 10.2 BRCA1 BRCA2 RAD51D TP53
25 nasal cavity disease 10.2 BRCA1 BRCA2 RAD51D TP53
26 progesterone-receptor positive breast cancer 10.2 BRCA1 BRCA2 TP53
27 villoglandular endometrial endometrioid adenocarcinoma 10.2 BRCA1 BRCA2 PTEN TP53
28 heart malignant hemangiopericytoma 10.2 BRCA1 BRCA2
29 nemaline myopathy 8, autosomal recessive 10.2 BRCA1 BRCA2 BRIP1 PALB2
30 neuropathy, distal hereditary motor, type viib 10.2 BRCA1 BRCA2 MLH1
31 bacteremia 10.2 BRCA1 BRCA2 MRE11 PALB2
32 glanders 10.2 BRCA2 BRIP1 RAD51
33 uterine corpus endometrial stromal sarcoma 10.1 BRCA1 MLH1 TP53
34 polyembryoma of the ovary 10.1 BRCA1 BRCA2 CHEK2 PTEN RAD51
35 progesterone resistance 10.1 CHEK2 MRE11 NBN RAD50
36 prostatic adenoma 10.0 MLH1 PTEN TP53
37 submucosal invasive colon adenocarcinoma 10.0 BRCA2 STK11 TP53
38 fibromatosis, gingival, 1 10.0 MLH1 PMS1 PTEN
39 bardet-biedl syndrome 10.0 BRCA1 BRCA2 MLH1 PTEN TP53
40 nevoid hypermelanosis, linear and whorled 10.0 BRCA1 BRCA2 MLH1 PTEN TP53
41 bronchogenic cyst 10.0 BRCA1 BRCA2 BRIP1 CHEK2 PALB2 PTEN
42 childhood teratocarcinoma of the testis 9.9 BRCA1 BRCA2 PTEN STK11
43 herpes simplex encephalitic 6 9.9 BRCA2 PTEN STK11 TP53
44 t-cell large granular lymphocyte leukemia 9.9 MLH1 PMS1 PTEN TP53
45 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 9.9 BRCA2 PTEN STK11 TP53
46 peroxisome biogenesis disorder 5b 9.9 BRCA1 CHEK2 MRE11 NBN RAD50 TP53
47 muscular dystrophy-dystroglycanopathy , type b, 2 9.9 BRCA1 BRCA2 MLH1 PTEN TP53
48 prostate cancer, hereditary, x-linked 1 9.9 PTEN STK11 TP53
49 epidermolysis bullosa, nonspecific, autosomal recessive 9.9 BRCA1 CHEK2 MRE11 NBN RAD50 TP53
50 pituitary stalk meningioma 9.9 BARD1 BRCA1 BRCA2 CHEK2 PTEN RAD51

Graphical network of the top 20 diseases related to Hereditary Breast Ovarian Cancer:



Diseases related to Hereditary Breast Ovarian Cancer

Symptoms & Phenotypes for Hereditary Breast Ovarian Cancer

GenomeRNAi Phenotypes related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.83 BRCA1 RAD51 BARD1 XRCC2
2 Decreased homologous recombination repair frequency GR00151-A-2 10.83 BRCA1 RAD51 XRCC2
3 Decreased homologous recombination repair frequency GR00236-A-1 10.83 BRCA2 PALB2 RAD51 BRCA1 BARD1
4 Decreased homologous recombination repair frequency GR00236-A-2 10.83 BRCA2 PALB2 RAD51 BRCA1 BARD1 IGFBP4
5 Decreased homologous recombination repair frequency GR00236-A-3 10.83 BRCA1 BRCA2 PALB2 RAD51 BARD1
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.42 CHEK2 MLH1 MRE11 NBN PALB2 PTEN
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.42 BRIP1 CHEK2 MLH1 MRE11 NBN PALB2
8 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 10.16 CHEK2 MLH1 MRE11 NBN PALB2 PMS1
9 Increased cell death HMECs cells GR00103-A-0 9.8 RAD51 RAD51C TP53 BRCA1 IGFBP4 PTEN
10 Decreased viability with cisplatin GR00101-A-4 9.77 BARD1 BRCA1 BRCA2 BRIP1 RAD51
11 Synthetic lethal with cisplatin GR00101-A-1 9.55 BARD1 BRCA1 BRCA2 BRIP1 RAD51
12 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BARD1 BRCA1 BRCA2 MRE11 RAD51D

MGI Mouse Phenotypes related to Hereditary Breast Ovarian Cancer:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 MLH1 MRE11 NBN PALB2 PTEN RAD50
2 embryo MP:0005380 10.34 BARD1 BRCA1 BRCA2 MRE11 NBN PALB2
3 growth/size/body region MP:0005378 10.3 BARD1 BRCA1 BRCA2 IGFBP4 NBN PALB2
4 endocrine/exocrine gland MP:0005379 10.26 BRCA1 BRCA2 BRIP1 CHEK2 IGFBP4 MLH1
5 homeostasis/metabolism MP:0005376 10.25 BRCA1 BRCA2 BRIP1 CHEK2 IGFBP4 MLH1
6 mortality/aging MP:0010768 10.22 BARD1 BRCA1 BRCA2 CHEK2 MLH1 MRE11
7 neoplasm MP:0002006 10.13 MRE11 NBN PALB2 PMS1 PTEN RAD50
8 integument MP:0010771 10.06 BRCA1 BRCA2 MLH1 PALB2 PTEN RAD50
9 digestive/alimentary MP:0005381 10.05 BRCA1 BRCA2 MLH1 PTEN RAD50 STK11
10 nervous system MP:0003631 10 MRE11 NBN PALB2 PTEN RAD50 RAD51D
11 limbs/digits/tail MP:0005371 9.97 XRCC2 BRCA1 BRCA2 PALB2 PTEN RAD50
12 reproductive system MP:0005389 9.7 MLH1 MRE11 NBN PTEN RAD50 RAD51C
13 respiratory system MP:0005388 9.17 TP53 XRCC2 BRCA1 MLH1 PTEN RAD50

Drugs & Therapeutics for Hereditary Breast Ovarian Cancer

Drugs for Hereditary Breast Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
2 Hormone Antagonists Phase 3,Phase 2
3 Hormones Phase 3,Phase 2
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
5 Estrogen Antagonists Phase 3,Phase 2
6 Estrogens Phase 3,Phase 2
7 Steroid Synthesis Inhibitors Phase 3
8 Aromatase Inhibitors Phase 3
9
Zoledronic acid Approved Phase 2 118072-93-8 68740
10
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
11
Tamoxifen Approved Phase 2 10540-29-1 2733526
12
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
13
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
14
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
15
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
16
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
17
Doxil Approved June 1999 Phase 2 31703
18 Diphosphonates Phase 2
19 Bone Density Conservation Agents Phase 2
20 Selective Estrogen Receptor Modulators Phase 2
21 Albumin-Bound Paclitaxel Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 2,Phase 1
23 Estrogen Receptor Modulators Phase 2
24 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
25 Immunosuppressive Agents Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 2,Phase 1
27 Antimitotic Agents Phase 2,Phase 1
28 Antineoplastic Agents, Hormonal Phase 2
29 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
30
tremelimumab Phase 1, Phase 2
31 Alkylating Agents Phase 2
32 Topoisomerase Inhibitors Phase 2
33 Immunoglobulins Phase 1, Phase 2
34 Antibodies, Monoclonal Phase 1, Phase 2
35 Antibodies Phase 1, Phase 2
36 Antirheumatic Agents Phase 2
37 Antineoplastic Agents, Alkylating Phase 2
38 Citrate Nutraceutical Phase 2
39
Citric Acid Nutraceutical, Vet_approved Phase 2 77-92-9 311
40
Vinblastine Approved Phase 1 865-21-4 13342 241903
41
Vinorelbine Approved, Investigational Phase 1 71486-22-1 60780 44424639
42
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
43
Everolimus Approved Phase 1 159351-69-6 6442177
44
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
45
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
46
Veliparib Investigational Phase 1 912444-00-9 11960529
47 Anti-Infective Agents Phase 1
48 Antifungal Agents Phase 1
49
Ethanol Approved 64-17-5 702
50
Menthol Approved 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 69)
id Name Status NCT ID Phase
1 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
2 Guilford Genomic Medicine Initiative (GGMI) Completed NCT01372553 Phase 4
3 Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children Completed NCT00685256 Phase 3
4 Methods in Education for Breast Cancer Genetics Active, not recruiting NCT00001806 Phase 3
5 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3
6 Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Not yet recruiting NCT03162276 Phase 3
7 Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Unknown status NCT00305695 Phase 2
8 Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer Completed NCT01333748 Phase 2
9 Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Completed NCT01367639 Phase 2
10 Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer Completed NCT00253539 Phase 2
11 Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer Completed NCT00321633 Phase 2
12 The Women Choosing Surgical Prevention (WISP) Trial Recruiting NCT02760849 Phase 2
13 Neoadjuvant Carboplatin in Triple Negative Breast Cancer Recruiting NCT02978495 Phase 2
14 A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Recruiting NCT02203513 Phase 2
15 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting NCT02571725 Phase 1, Phase 2
16 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer Active, not recruiting NCT00679783 Phase 2
17 Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Completed NCT00535119 Phase 1
18 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1
19 Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Active, not recruiting NCT00892736 Phase 1
20 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer Active, not recruiting NCT01104259 Phase 1
21 Hypodontia and Ovarian Cancer Unknown status NCT01470235
22 Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer Unknown status NCT00855998
23 Korean Hereditary Breast Cancer Study Unknown status NCT00595348
24 Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Unknown status NCT01139957
25 Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment Unknown status NCT01273909
26 Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer Unknown status NCT01187602
27 Statewide Communication to Reach Diverse Low Income Women Completed NCT02956681
28 Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC) Completed NCT00829959
29 Telemedicine vs. Face-to-Face Cancer Genetic Counseling Completed NCT00609505
30 Cancer Genetics Hereditary Cancer Panel Testing Completed NCT02324062
31 Risk Education and Assessment for Cancer Heredity Completed NCT01346761
32 Lessons Learned From the Family Gene Toolkit Completed NCT02154633
33 Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer Completed NCT00001496
34 Microarray Analysis for Human Genetic Disease Completed NCT00001898
35 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed NCT00408681
36 Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk Completed NCT00735150
37 Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk Completed NCT00043472
38 Outcomes of Education and Counseling for BRCA1 Testing Completed NCT00001468
39 Adaptation to Living With a BRCA1/2 Mutation Completed NCT01866865
40 A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women Completed NCT00858078
41 Physicians Survey on Genetic Testing Completed NCT00341107
42 Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer Recruiting NCT03075540
43 Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk Recruiting NCT02705924
44 Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry Recruiting NCT02302742
45 Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers Recruiting NCT02516540
46 Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland Recruiting NCT03124212
47 Familial Cancer Registry and DNA Bank Recruiting NCT02083224
48 Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients Recruiting NCT01789684
49 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
50 Pancreatic Cancer Genetics Recruiting NCT01102569

Search NIH Clinical Center for Hereditary Breast Ovarian Cancer

Cochrane evidence based reviews: hereditary breast and ovarian cancer syndrome

Genetic Tests for Hereditary Breast Ovarian Cancer

Genetic tests related to Hereditary Breast Ovarian Cancer:

id Genetic test Affiliating Genes
1 Hereditary Breast and Ovarian Cancer Syndrome 29
2 Breast/ovarian Cancer, Hereditary 24

Anatomical Context for Hereditary Breast Ovarian Cancer

MalaCards organs/tissues related to Hereditary Breast Ovarian Cancer:

39
Breast, Testes, Ovary, Heart

Publications for Hereditary Breast Ovarian Cancer

Articles related to Hereditary Breast Ovarian Cancer:

(show top 50) (show all 75)
id Title Authors Year
1
Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. ( 26943589 )
2016
2
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. ( 27532258 )
2016
3
MA1llerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. ( 26875157 )
2016
4
Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer. ( 26969308 )
2016
5
Modeling the dyadic effects of parenting, stress, and coping on parent-child communication in families tested for hereditary breast-ovarian cancer risk. ( 26848859 )
2016
6
RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families. ( 26406419 )
2015
7
Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation? ( 26246179 )
2015
8
Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the creighton university hereditary cancer registry with review of the implications. ( 25756400 )
2015
9
BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. ( 26047126 )
2015
10
The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. ( 24916970 )
2014
11
The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. ( 22740372 )
2013
12
Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. ( 24021253 )
2013
13
Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment. ( 22777929 )
2013
14
Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. ( 23935836 )
2013
15
BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. ( 23697973 )
2012
16
Adverse childhood experiences of persons at risk for Huntington's disease or BRCA1/2 hereditary breast/ovarian cancer. ( 21895638 )
2012
17
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. ( 21203900 )
2011
18
Unpacking the blockers: understanding perceptions and social constraints of health communication in hereditary breast ovarian cancer (HBOC) susceptibility families. ( 21547418 )
2011
19
Hereditary breast ovarian cancer syndromes in the Maritimes. ( 20181317 )
2010
20
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. ( 20169665 )
2010
21
Hereditary breast-ovarian cancer syndrome in Russia. ( 22649661 )
2010
22
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. ( 23199084 )
2010
23
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. ( 19008092 )
2009
24
The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects. ( 20149041 )
2009
25
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. ( 19178933 )
2009
26
Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS). ( 18385162 )
2009
27
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. ( 19820364 )
2009
28
BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. ( 19241424 )
2009
29
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. ( 18821011 )
2009
30
Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. ( 19292801 )
2009
31
Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. ( 19016756 )
2008
32
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. ( 18410690 )
2008
33
BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer. ( 18417966 )
2008
34
Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases. ( 19066131 )
2008
35
Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer. ( 18219587 )
2008
36
Hereditary breast-ovarian cancer: clinical findings and medical management. ( 17901820 )
2007
37
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. ( 17898808 )
2007
38
A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer. ( 17131039 )
2007
39
Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. ( 16527602 )
2006
40
Acceptance of genetic testing for hereditary breast ovarian cancer among study enrollees from an African American kindred. ( 16523520 )
2006
41
Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families. ( 16465413 )
2006
42
Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. ( 16980814 )
2006
43
Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. ( 16252621 )
2005
44
Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations". ( 16188301 )
2005
45
The effect of experiential knowledge on construction of risk perception in hereditary breast/ovarian cancer. ( 15789156 )
2005
46
Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia. ( 20223033 )
2005
47
Decision making and decision support for hereditary breast-ovarian cancer susceptibility. ( 16045423 )
2005
48
Hereditary Breast-Ovarian Cancer Team of the University Medical Centre Groningen (UMCG) - a Report. ( 20223045 )
2005
49
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. ( 15863145 )
2005
50
Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. ( 15846789 )
2005

Variations for Hereditary Breast Ovarian Cancer

ClinVar genetic disease variations for Hereditary Breast Ovarian Cancer:

6 (show top 50) (show all 805)
id Gene Variation Type Significance SNP ID Assembly Location
1 BRCA2 NM_000059.3(BRCA2): c.6275_6276delTT (p.Leu2092Profs) deletion Pathogenic rs11571658 GRCh37 Chromosome 13, 32914767: 32914768
2 BRCA2 NM_000059.3(BRCA2): c.6591_6592delTG (p.Glu2198Asnfs) deletion Pathogenic rs80359605 GRCh37 Chromosome 13, 32915083: 32915084
3 BRCA2 NM_000059.3(BRCA2): c.5722_5723delCT (p.Leu1908Argfs) deletion Pathogenic rs80359530 GRCh37 Chromosome 13, 32914214: 32914215
4 BRCA2 NM_000059.3(BRCA2): c.2808_2811del4 (p.Ala938Profs) deletion Pathogenic rs80359351 GRCh37 Chromosome 13, 32911300: 32911303
5 BRCA2 NM_000059.3(BRCA2): c.5946delT (p.Ser1982Argfs) deletion Pathogenic rs80359550 GRCh37 Chromosome 13, 32914438: 32914438
6 BRCA2 NM_000059.3(BRCA2): c.771_775delTCAAA (p.Asn257Lysfs) deletion Pathogenic rs80359671 GRCh37 Chromosome 13, 32905145: 32905149
7 BRCA2 NM_000059.3(BRCA2): c.8537_8538delAG (p.Glu2846Glyfs) deletion Pathogenic rs80359714 GRCh37 Chromosome 13, 32945142: 32945143
8 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
9 BRCA2 NM_000059.3(BRCA2): c.4648G> T (p.Glu1550Ter) single nucleotide variant Pathogenic rs80358695 GRCh37 Chromosome 13, 32913140: 32913140
10 BRCA2 NM_000059.3(BRCA2): c.9196C> T (p.Gln3066Ter) single nucleotide variant Pathogenic rs80359180 GRCh37 Chromosome 13, 32954222: 32954222
11 BRCA2 NM_000059.3(BRCA2): c.631+1G> A single nucleotide variant Pathogenic rs81002897 GRCh37 Chromosome 13, 32900751: 32900751
12 BRCA2 NM_000059.3(BRCA2): c.631+2T> G single nucleotide variant Pathogenic rs81002899 GRCh37 Chromosome 13, 32900752: 32900752
13 BRCA1 NM_007294.3(BRCA1): c.181T> G (p.Cys61Gly) single nucleotide variant Pathogenic rs28897672 GRCh37 Chromosome 17, 41258504: 41258504
14 BRCA1 NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs) deletion Pathogenic rs80357783 GRCh37 Chromosome 17, 41276047: 41276048
15 BRCA1 NM_007294.3(BRCA1): c.1175_1214del40 (p.Leu392Glnfs) deletion Pathogenic rs80359874 GRCh37 Chromosome 17, 41246334: 41246373
16 BRCA1 NM_007294.3(BRCA1): c.2681_2682delAA (p.Lys894Thrfs) deletion Pathogenic rs80357971 GRCh37 Chromosome 17, 41244866: 41244867
17 BRCA1 NM_007294.3(BRCA1): c.3005delA (p.Asn1002Thrfs) deletion Pathogenic rs80357601 GRCh37 Chromosome 17, 41244543: 41244543
18 BRCA1 NM_007294.3(BRCA1): c.3607C> T (p.Arg1203Ter) single nucleotide variant Pathogenic rs62625308 GRCh37 Chromosome 17, 41243941: 41243941
19 BRCA1 NM_007294.3(BRCA1): c.3748G> T (p.Glu1250Ter) single nucleotide variant Pathogenic rs28897686 GRCh37 Chromosome 17, 41243800: 41243800
20 BRCA1 NM_007294.3(BRCA1): c.3756_3759delGTCT (p.Ser1253Argfs) deletion Pathogenic rs80357868 GRCh37 Chromosome 17, 41243789: 41243792
21 BRCA1 NM_007294.3(BRCA1): c.4065_4068delTCAA (p.Asn1355Lysfs) deletion Pathogenic rs80357508 GRCh37 Chromosome 17, 41243480: 41243483
22 BRCA1 NM_007294.3(BRCA1): c.4327C> T (p.Arg1443Ter) single nucleotide variant Pathogenic rs41293455 GRCh37 Chromosome 17, 41234451: 41234451
23 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
24 BRCA1 NM_007294.3(BRCA1): c.843_846delCTCA (p.Ser282Tyrfs) deletion Pathogenic rs80357919 GRCh37 Chromosome 17, 41246702: 41246705
25 BRCA1 NM_007294.3(BRCA1): c.3481_3491delGAAGATACTAG (p.Glu1161Phefs) deletion Pathogenic rs80357877 GRCh37 Chromosome 17, 41244057: 41244067
26 BRCA1 NM_007294.3(BRCA1): c.211A> G (p.Arg71Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80357382 GRCh37 Chromosome 17, 41258474: 41258474
27 BRCA1 NM_007294.3(BRCA1): c.5324T> G (p.Met1775Arg) single nucleotide variant Pathogenic rs41293463 GRCh37 Chromosome 17, 41203088: 41203088
28 BRCA1 NM_007294.3(BRCA1): c.135-1G> T single nucleotide variant Pathogenic rs80358158 GRCh37 Chromosome 17, 41258551: 41258551
29 BRCA1 NM_007294.3(BRCA1): c.1360_1361delAG (p.Ser454Terfs) deletion Pathogenic rs80357969 GRCh37 Chromosome 17, 41246187: 41246188
30 BRCA1 NM_007294.3(BRCA1): c.1389_1390delAAinsG (p.Thr464Profs) indel Pathogenic rs273897659 GRCh37 Chromosome 17, 41246158: 41246159
31 BRCA1 NM_007294.3(BRCA1): c.143delT (p.Met48Serfs) deletion Pathogenic rs80357637 GRCh37 Chromosome 17, 41258542: 41258542
32 BRCA1 NM_007294.3(BRCA1): c.1444_1447delATTA (p.Ile482Terfs) deletion Pathogenic rs80357801 GRCh37 Chromosome 17, 41246101: 41246104
33 BRCA1 NM_007294.3(BRCA1): c.1480C> T (p.Gln494Ter) single nucleotide variant Pathogenic rs80357010 GRCh37 Chromosome 17, 41246068: 41246068
34 BRCA1 NM_007294.3(BRCA1): c.1504_1508delTTAAA (p.Leu502Alafs) deletion Pathogenic rs80357888 GRCh37 Chromosome 17, 41246040: 41246044
35 BRCA1 NM_007294.3(BRCA1): c.1674delA (p.Gly559Valfs) deletion Pathogenic rs80357600 GRCh37 Chromosome 17, 41245874: 41245874
36 BRCA1 NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter) single nucleotide variant Pathogenic rs80356898 GRCh37 Chromosome 17, 41245861: 41245861
37 BRCA1 NM_007294.3(BRCA1): c.1953_1956delGAAA (p.Lys653Serfs) deletion Pathogenic rs80357526 GRCh37 Chromosome 17, 41245592: 41245595
38 BRCA1 NM_007294.3(BRCA1): c.1960A> T (p.Lys654Ter) single nucleotide variant Pathogenic rs80357355 GRCh37 Chromosome 17, 41245588: 41245588
39 BRCA1 NM_007294.3(BRCA1): c.1961delA (p.Lys654Serfs) deletion Pathogenic rs80357522 GRCh37 Chromosome 17, 41245587: 41245587
40 BRCA1 NM_007294.3(BRCA1): c.2071delA (p.Arg691Aspfs) deletion Pathogenic rs80357688 GRCh37 Chromosome 17, 41245477: 41245477
41 BRCA1 NM_007294.3(BRCA1): c.2105dupT (p.Leu702Phefs) duplication Pathogenic rs80357880 GRCh37 Chromosome 17, 41245443: 41245443
42 BRCA1 NM_007294.3(BRCA1): c.213-11T> G single nucleotide variant Pathogenic rs80358061 GRCh37 Chromosome 17, 41256984: 41256984
43 BRCA1 NM_007294.3(BRCA1): c.213-12A> G single nucleotide variant Pathogenic rs80358163 GRCh37 Chromosome 17, 41256985: 41256985
44 BRCA1 NM_007294.3(BRCA1): c.2138C> G (p.Ser713Ter) single nucleotide variant Pathogenic rs80357233 GRCh37 Chromosome 17, 41245410: 41245410
45 BRCA1 NM_007294.3(BRCA1): c.2210_2211delCA (p.Thr737Serfs) deletion Pathogenic rs80357654 GRCh37 Chromosome 17, 41245337: 41245338
46 BRCA1 NM_007294.3(BRCA1): c.2411_2412delAG (p.Gln804Leufs) deletion Pathogenic rs80357664 GRCh37 Chromosome 17, 41245136: 41245137
47 BRCA1 NM_007294.3(BRCA1): c.2433delC (p.Lys812Argfs) deletion Pathogenic rs80357524 GRCh37 Chromosome 17, 41245115: 41245115
48 BRCA1 NM_007294.3(BRCA1): c.2457delC (p.Asp821Ilefs) deletion Pathogenic rs80357669 GRCh37 Chromosome 17, 41245091: 41245091
49 BRCA1 NM_007294.3(BRCA1): c.2475delC (p.Asp825Glufs) deletion Pathogenic rs80357970 GRCh37 Chromosome 17, 41245073: 41245073
50 BRCA1 NM_007294.3(BRCA1): c.2563C> T (p.Gln855Ter) single nucleotide variant Pathogenic rs80357131 GRCh37 Chromosome 17, 41244985: 41244985

Expression for Hereditary Breast Ovarian Cancer

Search GEO for disease gene expression data for Hereditary Breast Ovarian Cancer.

Pathways for Hereditary Breast Ovarian Cancer

Pathways related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 BARD1 BRCA1 BRIP1 CHEK2 MLH1 MRE11
2
Show member pathways
13.5 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
3
Show member pathways
13.2 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
4
Show member pathways
13.06 BARD1 BRCA1 BRIP1 CHEK2 MLH1 MRE11
5
Show member pathways
13.01 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
6
Show member pathways
12.78 BARD1 BRCA1 BRCA2 CHEK2 MRE11 NBN
7
Show member pathways
12.75 BARD1 BRCA1 BRIP1 CHEK2 MRE11 NBN
8 12.63 BRCA2 MLH1 PTEN RAD51 TP53
9
Show member pathways
12.61 BRCA1 BRCA2 MLH1 MRE11 NBN RAD50
10 12.6 BRCA1 BRCA2 BRIP1 CHEK2 MLH1 MRE11
11
Show member pathways
12.5 BARD1 BRCA1 CHEK2 MRE11 NBN RAD50
12
Show member pathways
12.5 BRCA1 CHEK2 MRE11 NBN PTEN RAD50
13
Show member pathways
12.33 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
14
Show member pathways
12.3 MRE11 NBN RAD50 TP53
15
Show member pathways
12.21 BRCA1 CHEK2 PTEN TP53
16 12.13 CHEK2 MLH1 PTEN STK11 TP53
17
Show member pathways
12.12 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
18 12.03 BRCA1 BRCA2 BRIP1 MLH1 PALB2 RAD51
19
Show member pathways
11.96 BRCA1 CHEK2 MRE11 NBN RAD50 RAD51
20 11.84 BARD1 BRCA1 BRCA2 CHEK2 MRE11 PTEN
21 11.73 BRCA1 CHEK2 PTEN TP53
22 11.69 BRCA1 MLH1 TP53
23 11.64 MRE11 NBN RAD50
24 11.64 CHEK2 MRE11 NBN RAD50 STK11
25 11.61 BARD1 BRCA1 CHEK2 NBN TP53
26 11.61 BARD1 BRCA1 CHEK2 MRE11 PTEN RAD50
27 11.37 BARD1 BRCA1 MRE11 NBN RAD50 RAD51
28 11.28 BRCA1 MRE11 NBN RAD50
29
Show member pathways
11.2 BARD1 BRCA1 BRCA2 CHEK2 MRE11 NBN
30
Show member pathways
11.15 MRE11 NBN RAD50
31
Show member pathways
11 MRE11 NBN RAD50
32 10.33 CHEK2 TP53

GO Terms for Hereditary Breast Ovarian Cancer

Cellular components related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 chromosome GO:0005694 9.99 BRCA1 MLH1 MRE11 NBN RAD50 RAD51D
2 condensed nuclear chromosome GO:0000794 9.78 BRCA1 MLH1 RAD50 RAD51
3 site of double-strand break GO:0035861 9.73 MRE11 NBN RAD50 RAD51
4 nuclear chromosome, telomeric region GO:0000784 9.73 BRCA2 MRE11 NBN RAD50 RAD51 RAD51D
5 chromosome, telomeric region GO:0000781 9.72 CHEK2 MRE11 NBN RAD50 RAD51D
6 condensed chromosome GO:0000793 9.71 BRCA1 MLH1 RAD51
7 lateral element GO:0000800 9.67 BRCA1 BRCA2 RAD51
8 Mre11 complex GO:0030870 9.63 MRE11 NBN RAD50
9 PML body GO:0016605 9.63 CHEK2 MRE11 NBN PTEN RAD51 TP53
10 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 9.58 RAD51C RAD51D XRCC2
11 MutLalpha complex GO:0032389 9.56 MLH1 PMS1
12 BRCA1-A complex GO:0070531 9.55 BARD1 BRCA1
13 nucleoplasm GO:0005654 9.55 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
14 BRCA1-BARD1 complex GO:0031436 9.52 BARD1 BRCA1
15 replication fork GO:0005657 9.35 NBN RAD51C RAD51D TP53 XRCC2
16 nucleus GO:0005634 10.32 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1

Biological processes related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.98 BARD1 NBN STK11 TP53
2 double-strand break repair via nonhomologous end joining GO:0006303 9.97 BARD1 BRCA1 MLH1 MRE11 NBN RAD50
3 response to ionizing radiation GO:0010212 9.95 BRCA1 RAD51C RAD51D STK11 XRCC2
4 reciprocal meiotic recombination GO:0007131 9.95 MLH1 MRE11 RAD50 RAD51 RAD51C RAD51D
5 DNA synthesis involved in DNA repair GO:0000731 9.93 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
6 DNA duplex unwinding GO:0032508 9.92 BRIP1 MRE11 NBN RAD50
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.92 BRCA1 BRCA2 CHEK2 MLH1
8 response to gamma radiation GO:0010332 9.9 BRCA2 CHEK2 TP53 XRCC2
9 cellular response to hypoxia GO:0071456 9.89 BRIP1 PTEN TP53
10 telomere maintenance via recombination GO:0000722 9.89 BRCA2 RAD50 RAD51 RAD51C
11 DNA double-strand break processing GO:0000729 9.88 BARD1 BRCA1 MRE11 NBN RAD50
12 nucleotide-excision repair GO:0006289 9.86 BRCA2 RAD51D TP53
13 telomere maintenance GO:0000723 9.86 NBN RAD50 RAD51D
14 response to X-ray GO:0010165 9.86 BRCA2 RAD51 TP53 XRCC2
15 DNA damage checkpoint GO:0000077 9.85 BRIP1 CHEK2 NBN
16 synapsis GO:0007129 9.85 BRIP1 MLH1 MRE11
17 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.84 BRCA2 CHEK2 TP53
18 meiotic nuclear division GO:0007126 9.84 MLH1 RAD51 XRCC2
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.84 BRCA1 BRCA2 CHEK2 TP53
20 chromosome organization GO:0051276 9.83 BRCA2 MRE11 RAD51D
21 cellular response to gamma radiation GO:0071480 9.83 CHEK2 RAD51 TP53
22 mitotic recombination GO:0006312 9.83 RAD51 RAD51C RAD51D XRCC2
23 positive regulation of protein autophosphorylation GO:0031954 9.82 MRE11 NBN RAD50
24 positive regulation of kinase activity GO:0033674 9.81 MRE11 NBN RAD50
25 strand invasion GO:0042148 9.81 RAD51 RAD51C RAD51D XRCC2
26 positive regulation of telomere maintenance GO:0032206 9.8 MRE11 NBN RAD50
27 meiotic DNA recombinase assembly GO:0000707 9.76 RAD51C RAD51D XRCC2
28 telomeric 3 overhang formation GO:0031860 9.75 MRE11 NBN RAD50
29 strand displacement GO:0000732 9.73 BARD1 BRCA1 BRCA2 BRIP1 MRE11 NBN
30 DNA damage response, signal transduction by p53 class mediator GO:0030330 9.71 NBN TP53
31 isotype switching GO:0045190 9.71 MLH1 NBN
32 mitotic G2 DNA damage checkpoint GO:0007095 9.71 MRE11 NBN
33 inner cell mass cell proliferation GO:0001833 9.7 BRCA2 PALB2
34 replicative senescence GO:0090399 9.7 CHEK2 TP53
35 protein K6-linked ubiquitination GO:0085020 9.69 BARD1 BRCA1
36 chromosome organization involved in meiotic cell cycle GO:0070192 9.69 RAD50 RAD51
37 negative regulation of telomere capping GO:1904354 9.69 NBN RAD50
38 chordate embryonic development GO:0043009 9.68 BRCA1 BRCA2
39 regulation of mitotic recombination GO:0000019 9.65 MRE11 RAD50
40 mitotic recombination-dependent replication fork processing GO:1990426 9.65 BRCA2 RAD51
41 double-strand break repair via homologous recombination GO:0000724 9.32 BRCA1 BRCA2 MRE11 NBN PALB2 RAD50
42 cellular response to DNA damage stimulus GO:0006974 10.25 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
43 cell cycle GO:0007049 10.21 BRCA1 BRCA2 CHEK2 MLH1 NBN RAD50
44 DNA repair GO:0006281 10.13 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
45 cell proliferation GO:0008283 10.11 BRCA2 IGFBP4 MRE11 NBN PTEN TP53
46 negative regulation of apoptotic process GO:0043066 10.1 BARD1 MRE11 PALB2 PTEN TP53
47 spermatogenesis GO:0007283 10.09 BRCA2 BRIP1 MLH1 RAD51C STK11
48 regulation of signal transduction by p53 class mediator GO:1901796 10.09 BARD1 BRCA1 BRIP1 CHEK2 MRE11 NBN
49 DNA replication GO:0006260 10.04 BARD1 BRCA1 BRIP1 MRE11 NBN RAD50
50 DNA recombination GO:0006310 10.02 BRCA1 BRCA2 MRE11 PALB2 RAD50 RAD51

Molecular functions related to Hereditary Breast Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.95 BRIP1 CHEK2 RAD50 RAD51 RAD51C RAD51D
2 double-stranded DNA binding GO:0003690 9.85 MRE11 RAD51 RAD51C RAD51D XRCC2
3 DNA-dependent ATPase activity GO:0008094 9.71 RAD51 RAD51C RAD51D XRCC2
4 damaged DNA binding GO:0003684 9.69 BRCA1 NBN TP53
5 ATP-dependent DNA helicase activity GO:0004003 9.67 BRIP1 MRE11 NBN RAD50
6 endodeoxyribonuclease activity GO:0004520 9.56 MRE11 RAD51 RAD51D XRCC2
7 mismatched DNA binding GO:0030983 9.54 MLH1 PMS1
8 single-stranded DNA endodeoxyribonuclease activity GO:0000014 9.49 MRE11 RAD50
9 four-way junction DNA binding GO:0000400 9.46 RAD51 RAD51C RAD51D XRCC2
10 recombinase activity GO:0000150 9.26 RAD51 RAD51C RAD51D XRCC2
11 single-stranded DNA binding GO:0003697 9.17 BRCA2 MLH1 PMS1 RAD51 RAD51C RAD51D
12 protein binding GO:0005515 10.45 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 MLH1
13 DNA binding GO:0003677 10.21 BRCA1 BRCA2 BRIP1 MRE11 PALB2 PMS1
14 ATP binding GO:0005524 10.06 BRIP1 CHEK2 MLH1 PMS1 RAD50 RAD51

Sources for Hereditary Breast Ovarian Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....